A Look Back on New and Emerging Data in MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: November 18, 2019
Expiration Date: November 18, 2020

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

It is critical that healthcare providers in the community setting remain up to date in the management of MDS. In this activity, you will hear from Dr. Guillermo Garcia-Manero and Dr. David Sallman on the advances made this year in MDS. This newsletter will cover recent studies that will impact practice and what to look for in the future.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with myelodysplastic syndromes
  • Outline clinical trials and recent advances in the management of serious disease-related conditions in MDS
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MDS

Agenda

A Look Back on New and Emerging Data in MDS – Guillermo Garcia-Manero, MD, and David Sallman, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 18, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Guillermo Garcia-Manero, MD
Professor
Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia 
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Guillermo Garcia-Manero received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London. He completed his internship and residency in internal medicine at Thomas Jefferson University Hospital in Philadelphia. He continued his training with a fellowship in hematology and medical oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, and Thomas Jefferson University Hospital, where he served as chief fellow. Dr. Garcia-Manero is currently a Professor in the Department of Leukemia and the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research at the University of Texas MD Anderson Cancer Center. He also serves as the Chief of the Section of Myelodysplastic Syndromes, Vice Chairman for Translational Research, Leader of the AML/MDS Moon Shot Program, and Program Director of the Leukemia Fellowship Program.

Dr. Garcia-Manero’s focus is on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for these patients. His work has been funded by NIH, DoD, LLS, CPRIT, and the MDS/AML Moon Shot project. He is currently PI/Co-PI on over 25 active AML/MDS clinical trials and has coauthored more than 682 manuscripts. Dr. Garcia-Manero directs one of the largest single institution units for patients with MDS and maintains one of the busiest clinics at MD Anderson. He has trained over 100 fellows and post-doctoral fellows and has been a speaker at multiple national and international forums. He has received numerous awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research. Dr. Garcia-Manero has also been recognized as one of the Best Doctors in America each year since 2007.

David A. Sallman, MD
Assistant Member
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Dr. David Sallman is an Assistant Member of the Malignant Hematology Department at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. His research interests focus on the development of novel, targeted therapeutic strategies for patients with myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) based on the underlying mutational drivers of the disease. Specifically, Dr. Sallman is involved in the study of the genetic drivers of myeloid diseases in order to improve prognostication for patients and also to allow for more personalized treatment. He has published significantly on this topic in peer-reviewed journals including Leukemia and Haematologica and this work is the foundation of clinical trials/translational studies designed to improve the quality of life and survival of patients with MDS. Dr. Sallman is also the principal investigator on multiple on-going studies focused on higher risk MDS.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-027-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Guillermo Garcia-Manero has received honoraria as a consultant from Amphivena Therapeutics, Inc., Astex Pharmaceuticals, and Celgene Corporation. He has received grant support related to research activities from AbbVie Inc., Amphivena, Astex, Celgene, H3 Biomedicine Inc., Helsinn Healthcare SA, Merck & Co., Inc., Novartis AG, and Onconova Therapeutics.

Dr. David Sallman has received honoraria related to speakers’ bureau activities from AbbVie Inc., Agios, Celgene Corporation, Incyte Corporation, and Novartis AG. He has received grant support related to research activities from Celgene and Jazz Pharmaceuticals plc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.